PFIZER REPORTS THIRD-QUARTER 2015 RESULTS

Go back to PFIZER REPORTS THIRD-QUARTER 2015 RESULTS

Cowen Remains Positive as Pfizer (PFE) Reports a 3Q Beat and raise

October 27, 2015 4:23 PM EDT

Cowen reiterated an Outperform rating and $43.00 price target on Pfizer (NYSE: PFE) following the company's 3Q earnings results. Q3 sales of $12,087MM (-2%) were $527MM above consensus. EPS of $0.60 (+5%) was $0.09 ahead of consensus. 2015 EPS guidance was raised to $2.16-2.20 from prior $2.04-2.10 range.... More

Pfizer (PFE) Tops Q3 EPS by 9c

October 27, 2015 6:46 AM EDT

Pfizer (NYSE: PFE) reported Q3 EPS of $0.60, $0.09 better than the analyst estimate of $0.51. Revenue for the quarter came in at $12.1 billion versus the consensus estimate of $11.56 billion.

EXECUTIVE COMMENTARY

Ian Read, Chairman and Chief Executive Officer, stated, Our business continues to demonstrate strength across key product lines and geographies which has resulted in another quarter of strong financial performance. We have been intently focused on seeking to generate a greater portion of our earnings from increased revenues and I see our product portfolio, product pipeline and recent business development activity as... More